Screener
Dyne Therapeutics, Inc. DYN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $100.89M-5.2% | $95.43M+16.7% | $97.22M+4.8% | $99.24M+59.4% | $106.45M+139% | ||
| $24.39M+53.1% | $20.7M+35.3% | $16.67M+29.7% | $16.56M+70.7% | $15.93M-35.3% | ||
| $125.28M+2.4% | $116.13M+19.6% | $113.89M+7.8% | $115.79M+60.9% | $122.37M+76.9% | ||
| -$125.28M-2.4% | -$116.13M-19.6% | -$113.89M-7.9% | -$115.79M-60.9% | -$122.37M-76.9% | ||
| $4.2M— | $3.19M— | $2.9M— | $94K— | $0— | ||
| $4.42M-36.9% | $4.17M-44.8% | $5.85M-31.4% | $4.93M-28.1% | $7.01M+99.9% | ||
| -$120.85M-4.8% | -$111.96M-25.0% | -$108.04M-11.2% | -$110.86M-70.3% | -$115.36M-75.7% | ||
| -$0.73+30.5% | -$0.73+17.0% | -$0.76+20.8% | -$0.97-38.6% | -$1.05-29.6% | ||
| -$124.73M-2.3% | -$115.61M-19.6% | -$113.39M-7.8% | -$115.29M-61.1% | -$121.87M-77.2% | ||
| -$125.28M-2.4% | -$116.13M-19.6% | -$113.89M-7.9% | -$115.79M-60.9% | -$122.37M-76.9% |
FAQ
- Is Dyne Therapeutics, Inc. profitable?
- Dyne Therapeutics, Inc. is not currently profitable: it reported a net loss of $451.7M over the trailing twelve months.
- What is Dyne Therapeutics, Inc.'s earnings per share?
- Dyne Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.19.
- Where does Dyne Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.